I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.
September 20, 2017
I count five (5) names of potential implosions … even with sudden new highs or money input
The question is, how do they avoid the BOD suits, NASDAQ listing and the SEC review?
Preview RMi's morning call. You’d be reading this if you were a SUBSCRIBER!
Pre-open indications: 0 BUY and 5 SELLs
If you had been right as many times as I have been in these many months of 2017 as a SUBSCRIBER you would know when to get in and out or get back in again! It’s called premium content for a reason: I reporting the truth in this sector!
September 18, 2017
After a hyped release, resorting to compensating “pushers” to drive momentum is injudicious in this climate ...
September 19, 2017
… For its cannons to fire and repel the downside takers
Pirates are needed to drive back the selling armadas; we need more buccaneers out there!
Pre-open indications: 6 hits and 1 miss (by pennies)
Out and about: Applied Genetic Technologies (AGTC) tries to see some upside and fails closing flat at $3.75 with 368.3 K shares traded <3 month average = 218.36 K shares>. Why CEO Washer hasn’t or doesn’t put her own money where her focus should have been …?
I answer one question, in which company should investors commit and keep their money. In the grip of rotating cycles and disparaging trends, what is the price of sector knowledge – a subscription!
August 31, 2017
VTGN is down -$0.10 or -5.50% to $1.72 A little heavy on the warrants to raise $2.4 million ...?
June 27, 2017
On track for top-line 1 year powered data and potential BLA filing in Q3/18 BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019
June 26, 2017
BLUE closed down -$4.20 to $1.06.90 after Monday's -$0.90 or -0.80% to $111.10
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2017 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
